SVF
Level C· Early Human ResearchProspective Study

Cellular and molecular changes in the human osteoarthritic and aging hip pulvinar.

Tilouche B., Farhat S., Short S., Somyk M., Horton I., Beaulé P.

Prospective Study with a reported sample of 21 on Osteoarthritis, published in Osteoarthritis Cartilage (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Osteoarthritis Cartilage (2026)
Country
England
Reported sample size
21
PMID
41506594
DOI
10.1016/j.joca.2025.12.022

Abstract (original English)

Osteoarthritis (OA) is a multifaceted pathology characterized by complex signaling across joint tissues. The sub-synovial adipose tissue (ssAT) has been proposed to function as a stem cell reservoir, mechanosensor, neuroendocrine organ, and regulator of inflammation. We aimed to distinguish cellular and molecular changes in ssAT associated with OA from those related to normal aging. Pulvinar ssAT samples were collected from four groups: young patients without OA (<20 years, n=21), adults without OA (20-40 years, n=59), young patients with OA (<40 years, n=28), and older patients with OA (>70 years, n=27). Stem cell content, tissue architecture, and gene expression were assessed using colony-forming unit-fibroblast (CFU-f) assays, immunohistochemistry, and a targeted NanoString transcriptomic panel (Immunology v2). OA samples displayed a marked increase in mesenchymal stem/progenitor cells (MSPCs) compared to age-matched controls, a finding not observed with aging alone. This expansion correlated with the upregulation of MSPC markers DPP4 and THY1. Both OA and aging were associated with remodeling of the immune landscape, characterized by reduced innate immune signatures, enrichment of exhausted CD8⁺ T cells, and transcriptional upregulation of inflammatory (e.g., IL6,MME) and fibroblast activation genes (THY1,DPP4). Vascular remodeling further distinguished OA from aging, while

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples, often without a control group.

How we grade evidence
HumansAgingFemaleAgedMaleMesenchymal Stem CellsAdultPulvinarOsteoarthritis, HipAdipose Tissue
Face & SkinHipOsteoarthritis
View on PubMedDOI

Related research